Tagg a day to throw 900 million into the new medicine Kanglong into, Kailaiying a crowd of CXO pile into

More and more CXO industry companies began to extend to the pharmaceutical industry, in the form of LPs through investment in early and medium-term pharmaceutical or medical companies, or direct equity investment, to participate in the domestic pharmaceutical innovation ecology to seek a piece of the pie.
October 20, Tiger Pharma issued six investment announcements in one breath, throwing 880 million yuan, this year Tiger Pharma has issued 15 related investment announcements, after a LP addiction.
Tyger, Pharmaceuticals had invested in 35 companies as a venture capital fund.
addition, Kanglonghuacheng, Kailaiying, Jiuzhou Pharmaceuticals, a group of CXO enterprises have also issued a number of investment in the establishment of industrial investment funds announced.
In recent years, the CXO industry has become a high-growth and stable gold industry, in the market competition pattern is stable, CXO companies holding a large amount of cash flow began to frequently through capital means, to participate in domestic pharmaceutical innovation ecology, in order to maximize the benefits.
20, Tiger Pharmaceuticals announced six investment announcements in one go, with a total investment of 880 million yuan.
, it is proposed to invest 600 million yuan in Suzhou Taifu Wai-jin Venture Capital Partnership (Limited Partnership), focusing on enterprises in biopharmaceuticals, biotechnology, medical health and related fields.
as an industry water delivery person, in August this year, Tag Pharmaceuticals became the third domestic "A-H" listed CRO company after the drug Mingkangde, Kanglong into.
, according to the Hong Kong prospectine, between 2017 and March 2020, Tiger Pharma participated in more than 400 clinical research projects worldwide and helped to market four liver and oncology drugs.
2019, Tiger Pharma is the only Chinese company in the top 10 in the world, with a domestic CRO market share of 8.4%.
, as a CRO company focused on late-stage clinical trials and data management, Tiger Pharmaceuticals has been investing.
statistics, Tagg Pharmaceuticals has only issued 15 investment announcements so far this year, with a total amount of 2 billion yuan to be paid out.
as of June 30, 2020, Tiger Pharmaceuticals was a strategic investor in 57 innovative companies and other companies in the healthcare industry and a limited partner of 39 pharmaceutical funds, according to its semi-annual report.
30 June this year, its non-listed fund investment reached 1.8 billion yuan, an increase of 73.06 percent over the end of the same period last year.
for frequent investment operations, Tiger Pharma has a base.
2019, Tiger Pharma CFO and company director Gao Jun once told the media that Tiger Pharma's investment income and the main business is more relevant, with a certain degree of sustainability.
on the one hand, Tiger Pharmaceuticals' operating performance remained high, with operating income of RMB1,452 million in the first half of this year, up 8.58 percent year-on-year and net profit of RMB999 million.
2019, Tiger Pharma's net profit was RMB842 million, an increase of 16.54 times over 2011 and 11.38 times over 2012.
and Tiger Pharmaceuticals had a low balance sheet ratio of 28.32 per cent at the end of June.
, on the other hand, Tiger Pharmaceuticals is still sitting on a rich investment return.
According to its semi-annual report data, the investment income from the disposal of other non-current financial assets and the fair value change income generated by other non-current assets, the combined income generated by the two items amounted to 657 million yuan.
Gaojun said that the company through direct investment, participation in medical investment funds and other ways to form a domestic innovative pharmaceutical clinical investment ecosystem.
Pharmaceuticals focuses on innovative biotechnology and medical devices, and invests in innovative projects that are in the early stages of research and development.
addition, Tiger Pharma regards investment in mergers and acquisitions as one of its core competencies and, through this means, continuously improves clinical research services.
, for example, the $50.25 million acquisition of a 67% stake in Fangda Pharmaceuticals of the United States in 2014 boosted the laboratory services capabilities of Tyger Pharmaceuticals, which will spin off Fangda Pharmaceuticals to list in Hong Kong in 2019.
2017, Tiger Pharma enhanced its medical device research and development services through the acquisition of Jetcom.
, on the other hand, Tiger Pharmaceuticals has invested in the global layout.
last three years, Tiger Pharma's domestic business accounted for 50%-60% of total revenue.
, but Tiger Pharma believes that relying on the domestic market alone is not enough to maintain the company's stable development.
acquired DreamCIS, one of South Korea's largest clinical CROs, as early as 2015, and according to Tag Pharmaceuticals co-founder Cao Xiaochun, Tiger Pharma also plans to acquire another company with a global layout.
through investment, Tiger Pharmaceuticals achieves not only win-win, but win-win.
Cao Xiaochun in an interview with the media, said that Tagg Pharmaceuticals is like a platform-based enterprises, contact with a wide range, can rely on their own experience, in the choice of projects have a certain advantage.
also through the cooperation of a number of projects, the reserve of fast-growing projects, but also a guarantee of Tiger's own business.
CXO enterprise industrial chain expansion in fact, in addition to Tag Pharmaceuticals, more and more CXO industry companies began to extend to the pharmaceutical industry, in the form of LPs through investment in early and medium-term pharmaceutical or medical companies, to participate in the domestic pharmaceutical innovation ecology in order to seek a piece of the pie.
the earliest industrial chain extension is the drug Mingkangde.
consensus in the industry is that Pharmaceuticals is the only company with a comprehensive layout in the outsourcing industry, covering the three stages of preclinical CRO, clinical CRO, CMO/CDMO, and is in the first echelon of CXO.
but not familiar with the B-side of Drug Mingkang, the company is also the most mature industrial investors.
Drug Mingkang's investment history began roughly in 2012, IT orange data show that as of the date of writing, Pharmaceutical Mingkangde as an enterprise venture capital fund has invested in 35 enterprises, of which A-wheel, B-round enterprises, a total of 22, mainly involved in drugs, equipment, testing and other technological innovation areas.
Overall, the current investment projects can be divided into two categories: one is for the drug Mingkangde research and development service platform to help the whole line layout of the project, the other is the drug Mingkangde research and development service platform can help the project.
In the U.S. market, DrugMind is primarily looking for technology and research and development leaders such as Calidus Biopharma, a small company that develops drugs for rare diseases and starts out with three employees - two scientists and a part-time finance.
the beginning of 2012, the company received investment from Pharmaceuticals, which later built cell strains, process development and small-scale production for animal model testing using the pharmaceutical biopharmaceutical research and development platform.
animal model tests soon became effective and were bought for $130 million by Amicus, a company that also works in the field of drug treatment for rare diseases.
a short-term deal for a perfect exit.
Huali Pharmaceuticals is the first domestic pharmaceutical company to disclose the investment of Chinese medicine Mingkangde, at the end of 2013, the world's first innovative drug dorzagliatin for diabetes products, Huali Pharmaceuticals received a 10 million U.S. dollars A round of financing from Drug Mingkangde and other institutions, when the valuation of 50 million U.S. dollars, followed by B round, round E and participated in 25 million U.S. dollars, 117 million U.S. dollars respectively.
2018, with the implementation of the New Deal on the Hong Kong Stock Exchange, Huali Pharmaceuticals became one of the first unprofitable listed pharmaceutical companies in Hong Kong, with a market capitalisation of HK$4.81 billion and a large book value.
the latest news is that China's Dorzagliatin has obtained a license to produce the drug.
drug clearly did not withdraw, but from the perspective of investment completion this is undoubtedly a successful exit case.
In addition, Drug Mingkang has invested in breakthrough cancer cell therapy company Drug Ming-Juno, gene diagnostic innovation company Foundation Medicine, subverting innovative DNA synthesis technology company Twist, etc. , the drug Ming-Min-No has passed the Hong Kong Stock Exchange hearing.
, in January 2015, Drug Mingkang was involved in a round A financing of Tianding Pharmaceuticals for $8 million, at a valuation of $40 million.
the company is a new generation of bioantibodies developers, as of the latest developments, Tianding Pharmaceuticals completed the D round of financing, after the investment valuation has reached $690 million.
the current financing schedule and capital market conditions, the company is likely to be listed in the next 1 to 2 years.
well-known innovation companies that have invested in the drug Mingkangde, as well as Beihai Kangcheng, Deqi Pharmaceuticals and so on.
it is worth noting that, as the number one player in CXO crab eating, the investment of Drug Mingkang has continued to grow over the past two years, with IT Orange counting that the number of cases from October 2017 to October 2020 was 5, 7, 8 and 6, respectively, and the amount increased from US$210 million to US$320 million.
benefits from multiple dividends such as MAH system and consistency evaluation, the CXO industry has become a high-growth and stable gold industry, CXO Head has formed a more stable market pattern.
it's not easy to quickly grab market share through your own business, CXO, which has a lot of cash flow in its hands, can only find another way to maximize its benefits.
On the one hand, relying on the large amount of cash flow brought about by the business, on the other hand, with the help of a relaxed financing environment in the secondary market to seek funds, such as Kailaiying, Tagg Pharmaceuticals, Zhao Yanxin, etc. have submitted fund-raising needs in the secondary market.
In addition to Tagg Pharmaceuticals, on October 20, Kanglonghuacheng announced that it would invest 100 million yuan of its own funds in Wuxi AstraZeneone Venture Capital Partnership to participate in the early and medium-term investment in pharmaceuticals.
Earlier, companies such as Jiuzhou Pharmaceuticals and Kailaiying made several announcements about their involvement in investing in the establishment of industrial investment funds, especially those such as Kaileiying, which have made few out-of-country investments, and have begun to broaden their scope through equity investments or fund investments.
CXO to the pharmaceutical industry integration is the domestic innovation under the "one-state", but also to walk in the forefront of a, this trend to a certain extent reflects the current hot current situation of innovative medicine, for the follow-up trend of the grasp of a lot of significance.